Implementation of a Hospital in the Home model for delivery of long-acting injectable antiretroviral therapy to people living with HIV: development, integration and early experience | Synapse
March 3, 2026
Implementation of a Hospital in the Home model for delivery of long-acting injectable antiretroviral therapy to people living with HIV: development, integration and early experience
Key Points
Delivery of long-acting injectable cabotegravir and rilpivirine in a home setting is feasible and safe.
Patients showed high acceptance of the Hospital in the Home model during early implementation.
The decentralized model could significantly improve access to HIV treatment in Australia.
Further exploration of broad adoption is warranted for long-term patient benefits.
Abstract
HITH delivery of cabotegravir/rilpivirine is feasible, safe and well accepted, providing a scalable, decentralised model for HIV treatment in Australia.